|
| [April 30, 2012] |
 |
Mediq Increases Its Homecare Market Share in the US with the Acquisition of Diabetes Specialty Center Through Its Byram Healthcare Subsidiary
WHITE PLAINS, New York --(Business Wire)--
Mediq, international supplier of medical devices and pharmaceuticals
which owns Byram
Healthcare, announced today the acquisition of Diabetes
Specialty Center (DSC). Salt Lake City-based DSC delivers
insulin pumps, continuous glucose monitors and related supplies to
frequent-users, insulin-dependent diabetics. This acquisition will
further solidify the White Plains, NY-based Byram in the number 4
position of this large but fragmented market.
Strategic rationale
-
The acquisition is in line with Mediq's strategy of further expanding
its direct activities, particularly in the US, increasing the scale of
Byram's operations
-
It provides Byram with an entry into the growth market of insulin
pumps, continuous glucose monitors and related supplies for
frequent-users, insulin-dependent, Type-1 diabetes patients
-
DSC's business model is very similar to that of Byram, enabling smooth
integration
-
The acquisition allows Mediq to achieve cost synergies in back-office
processes
Financial details
-
DSC realized sales of $26 million (€19.5 millon) in 2011
-
DSC's EBITA margin is slightly below the D&I segment average
-
The acquisition price of DSC amounts to $16 million (€12 million)
-
The acquisition will be financed from existing credit facilities
-
Mediq expects to achieve the ROCE pre-tax target of 15% by 2014
DSC, established in 2000, sells equipment (insulin pumps, continuous
glucose monitors) and related supplies and medication, mainly to
insulin-dependent, Type-1 diabetes patients. These patients are frequent
users to a much greater extent than Type-2 insulin-dependent patients.
Byram currently has no market share in the insulin pumps and continuous
glucose monitors market. DSC intends to be the center of excellence for
pumps and continuous glucose monitors as part of Byram. DSC, with 84
employees, has grown quickly over the past several years, in line with
the market.
Marc van Gelder, CEO of Mediq, said: "This is a logical step in the
buy-and-build strategy we have been pursuing in our Direct and
Institutional business over the past six years. With its scalable
infrastructure, Byram Healthcare provides us with a platform for further
growth in the large but fragmented US market. This acquisition greatly
enhances our position in a very interesting market segment. It also
presents us with the opportunity to grow on a local scale, which is
necessary to secure low costs to serve the market."
Marcel van den Broek, Executive Vice President of Mediq Direct &
Institutional: "We expect a smooth integration into our current
operations. DSC's business model is very similar to that of Byram. In
addition, DSC's CEO will be a member of Byram's management team."
The acquisition is expected to be finalized around the end of the second
quarter of 2012.
Byram Healthcare is a leading provider of disposable medical devices to
patients with chronic diseases. It has more than 40 years in service,
and is headquartered in White Plains, NY. Byram serves 300,000 patients
nationwide with 525 employees from 12 service locations and 4
distribution centers located across the US. For more information, see www.byramhealthcare.com.
Mediq is an international company delivering medical devices,
pharmaceuticals and related care services. The patient is at the center
of everything we do. Mediq delivers via three channels: direct to
people's homes (Direct), to professional customers such as hospitals,
nursing homes and GPs (Institutional) and via Mediq Pharmacies. Mediq
operates in 15 countries. Its head office is located in Utrecht, the
Netherlands. The company was founded in 1899 and has around 8,300
employees. Mediq is listed on NYSE Euronext Amsterdam. It reported € 2.7
billion in net sales in 2011. For more information, see www.mediq.com.

[ Back To SIP Trunking Home's Homepage ]
|